Use and monitoring of low dose rituximab in myasthenia gravis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 6, 2011, Pages 659-663

  Blum, Stefan ^a   Gillis, David ^b,c   Brown, Helen ^c   Boyle, Richard ^c   Henderson, Robert ^a   Heyworth Smith, David ^c   Hogan, Patrick ^b,c   Kubler, Paul ^a   Lander, Cecilie ^a   Limberg, Nicole ^d   Pillans, Peter ^c   Prain, Kerri ^b   Staples, Christopher ^e   Walsh, Michael ^c   McCombe, Pamela ^a   Wong, Richard ^b,c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b Pathology Queensland   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d St Andrews War Memorial Hospital   (Australia)

^e MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; MERCAPTOPURINE; METRONIDAZOLE; MUSCLE SPECIFIC KINASE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; AUSTRALIA; B CELL DEPLETION; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG USE; EOSINOPHILIA; FEMALE; FLOW CYTOMETRY; FLU LIKE SYNDROME; GIARDIASIS; HEAT SENSATION; HERPETIC STOMATITIS; HUMAN; HYPERTENSION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MALE; MYASTHENIA GRAVIS; PATIENT MONITORING; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TASTE DISORDER; THYMECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; B-LYMPHOCYTES; DRUG MONITORING; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RETROSPECTIVE STUDIES;

EID: 79955781847     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2010.220475     Document Type: Article

References (19)

1. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8. (Pubitemid 32224355)
2. Conti-Fine BM, Milani M, Wang W. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 2008;1132:193-209. (Pubitemid 351858541)
3. Masuda M, Matsumoto M, Tanaka S, et al. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol 2010;225:123-31.
4. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-66. (Pubitemid 44356635)
5. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010;47:170-9.
6. Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695-8. (Pubitemid 350248251)
7. Paul E, Roy F, Anna F-S, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
8. Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to rituximab in anti- AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;201-2:90-4.
9. Lebrun C, Bourg V, Tieulie N, et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-50.
10. Nelson RP Jr, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis 2009;10:170-7.
11. Stieglbauer K, Topakian R, Schaffer V, et al. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci 2009;280:120-2.
12. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82:671-3.
13. Zebardast N, Patwa HS, Novella SP, et al. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010;41:375-8.
14. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23. (Pubitemid 30460991)
15. Guptill J, Sanders B. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010;23:530-5.
16. Cornec D, Avouac J, Youinou P, et al. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009;8:515-19.
17. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006;33:575-80.
18. Liossis S-NC, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008;127:280-5.
19. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425-37.